ABVC BioPharma, Inc. (ABVC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABVC Stock Summary
- With a one year PEG ratio of 0.43, ABVC BIOPHARMA INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 4.95% of US stocks.
- ABVC BIOPHARMA INC's stock had its IPO on August 3, 2021, making it an older stock than merely 3.15% of US equities in our set.
- ABVC's price/sales ratio is 58.42; that's higher than the P/S ratio of 96.7% of US stocks.
- If you're looking for stocks that are quantitatively similar to ABVC BIOPHARMA INC, a group of peers worth examining would be SII, RETO, MTA, ZETA, and BRDG.
- ABVC's SEC filings can be seen here. And to visit ABVC BIOPHARMA INC's official web site, go to www.ambrivis.com.
ABVC Valuation Summary
- In comparison to the median Healthcare stock, ABVC's EV/EBIT ratio is 116.79% lower, now standing at -1.1.
- Over the past 20 months, ABVC's price/earnings ratio has gone up 7.2.
Below are key valuation metrics over time for ABVC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ABVC | 2023-03-17 | 57.1 | 3.3 | -1.0 | -1.1 |
| ABVC | 2023-03-16 | 54.2 | 3.1 | -1.0 | -1.1 |
| ABVC | 2023-03-15 | 55.1 | 3.2 | -1.0 | -1.1 |
| ABVC | 2023-03-14 | 61.2 | 3.5 | -1.1 | -1.2 |
| ABVC | 2023-03-13 | 55.1 | 3.2 | -1.0 | -1.1 |
| ABVC | 2023-03-10 | 56.3 | 3.3 | -1.0 | -1.1 |
ABVC Stock Price Chart Interactive Chart >
ABVC Price/Volume Stats
| Current price | $0.61 | 52-week high | $3.13 |
| Prev. close | $0.62 | 52-week low | $0.50 |
| Day low | $0.60 | Volume | 36,700 |
| Day high | $0.65 | Avg. volume | 914,568 |
| 50-day MA | $0.70 | Dividend yield | N/A |
| 200-day MA | $0.79 | Market Cap | 19.91M |
ABVC BioPharma, Inc. (ABVC) Company Bio
American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.
Latest ABVC News From Around the Web
Below are the latest news stories about ABVC BIOPHARMA INC that investors may wish to consider to help them evaluate ABVC as an investment opportunity.
ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in ThailandABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus® Phase II Site Initiation Visit (SIV) at Srinagarind Hospital, Khon Kaen University (TH002) was successfully conducted on March 9-10, 2023. The SIV was an organized meeting to discuss Phase II study protocol with the principal investigator and begin training clinical personnel. |
ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and WelfareABVC Biopharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that BioKey, a wholly-owned subsidiary of the Company based in Fremont, California, received an approval of Maitake Mushroom Dietary Supplement Tablet from Taiwan Ministry of Health and Welfare (MHW) on February 6, 2023. This approval served as an Import License (IL) for the shipment of Maitake M |
ABVC BioPharma Provides 2023 Pipeline UpdateFREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023. Major Depressive Disorder: ABVC’s MDD medicine, ABV-1504, has successfully completed Phase II at the Stanford University Medical Center and five major medical centers in Taiwan. Later this y |
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical TrialsFREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has closed a funding agreement for gross proceeds of $3.175 million (the "Investment") with Lind Global Fund II, LP, an investment fund managed by The Lind Partners (together “Investor” or “Lind”), a New York-based institutional fund manager. "We are ple |
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®FREMONT, CA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that approval to initiate the Phase II study of its Vitargus® medical device, in Australia, was received from the Australian Therapeutic Goods Administration (TGA) on February 9, 2023. Vitargus is the first biodegradable vitreous substitute to facilitate r |
ABVC Price Returns
| 1-mo | -16.45% |
| 3-mo | -11.59% |
| 6-mo | -31.45% |
| 1-year | -74.79% |
| 3-year | -76.98% |
| 5-year | N/A |
| YTD | -2.40% |
| 2022 | -81.56% |
| 2021 | -33.53% |
| 2020 | 16.70% |
| 2019 | -87.86% |
| 2018 | N/A |
Loading social stream, please wait...